The Miami Stem Cell Therapy Podcast

Ep. 20 Guide to Stem Cell Therapy for Common Conditions

To learn more about regenerative and restorative stem cell therapy treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
 
FULL TRANSCRIPT
Guide to Stem Cell Therapy for Common Conditions
Welcome to the STEMS Health Regenerative Medicine Podcast.I’m your host, and today we’re covering an important topic that often generates more questions than clear answers.
This episode is a condition-by-condition guide to stem cell therapy - what the science currently supports, where evidence is limited or mixed, and where treatments remain largely experimental.
Stem cell therapy is frequently discussed as a broad solution for many health problems. In reality, its potential benefits - and its limitations - depend heavily on the specific condition being treated. Evidence that supports one use does not automatically apply to another, even when similar types of cells are involved.
The goal of today’s episode is education. Not recommendations. Not promises. Just a clearer framework for understanding how stem cell therapy is actually studied and applied across different medical conditions, so patients can ask better questions and evaluate claims more critically.
Let’s start with an essential concept.
Stem cell therapy is not a single treatment.
It includes a range of approaches that differ based on tissue type - such as cartilage, tendon, nerve, or heart muscle - the underlying disease mechanism, the method of delivery, and the intended outcome. That outcome might be pain relief, functional improvement, immune modulation, or support for tissue signaling.
Because of these differences, evidence varies widely by condition. A therapy that shows promise for joint pain may not be biologically plausible - or clinically appropriate - for neurologic or autoimmune disease.
Understanding this variability is key to realistic expectations and safe decision-making.
Throughout this episode, we’ll refer to three broad evidence categories.
First, more established or stronger evidence. These are areas where multiple clinical studies exist and findings are relatively consistent, even though outcomes still vary and long-term data may be limited.
Second, limited or mixed evidence. These include small studies, early clinical trials, or inconsistent results. Some patients may benefit, but conclusions remain uncertain.
And third, primarily experimental. These applications are early-stage, often limited to laboratory research or small human trials. They are investigational and not considered standard care.
It’s important to note that stronger evidence does not mean guaranteed results. And experimental does not automatically mean unsafe. These categories simply reflect how much is known - and how much remains uncertain.
Now let’s look at specific conditions, starting with orthopedic and musculoskeletal uses.
Orthopedic conditions are among the most commonly discussed applications of stem cell therapy. That’s largely because joints and soft tissues are structurally defined, allowing for localized delivery rather than systemic treatment. Outcomes such as pain and function are also easier to measure, and the underlying degenerative and inflammatory mechanisms are better understood.
That said, evidence still varies significantly by condition.
Knee osteoarthritis is one of the most studied orthopedic applications. Research has focused on pain reduction, functional improvement, and changes in the joint environment.
The evidence here is moderate but mixed. Some studies report improvements in pain and mobility, particularly in earlier-stage disease. However, severity matters. Structural cartilage regeneration remains inconsistent, and results vary widely between patients. Importantly, stem cell therapy is not considered a replacement for joint replacement surgery in advanced arthritis.
Other joint conditions - such as the hip, shoulder, and ankle - follow similar principles, but the research is less extensive. Evidence is generally limited to moderate, with smaller studies, fewer long-term outcomes, and greater variability due to joint mechanics and load. Expectations should remain conservative, especially in advanced degeneration.
Tendon and ligament injuries are another area of interest because these tissues heal slowly due to limited blood supply. Research has explored whether stem cell therapy may help support the healing environment. Evidence here is limited and condition-specific. Some early studies suggest potential benefit, but outcomes depend heavily on injury severity, how long the injury has been present, and adherence to rehabilitation.
Spine and disc-related conditions are more complex. Research has focused on disc degeneration, pain modulation, and local inflammation. Evidence is early and mixed. Stem cell therapy does not address structural compression or instability, so careful diagnosis and patient selection are critical, and expectations should remain modest.
Now let’s move to neurologic conditions.
Neurologic applications generate significant interest but also present major biological challenges. Neurons have limited regenerative capacity. The brain and spinal cord are highly specialized. The blood-brain barrier limits delivery. And functional integration is difficult to achieve.
As a result, most neurologic uses remain research-focused.
In Parkinson’s disease, research has explored replacing dopamine-producing cells and modulating symptoms. Evidence remains experimental. Early clinical trials are ongoing, but long-term safety, durability, and functional integration are still unresolved. Stem cell therapy is not standard treatment for Parkinson’s disease.
Stroke research focuses on supporting recovery, enhancing neuroplasticity, and modulating inflammation. Evidence is investigational. Some studies suggest modest functional improvements, but results are inconsistent, and timing appears to be critical.
Conditions such as spinal cord injury, ALS, and multiple sclerosis are actively researched, but evidence remains primarily experimental. Most approaches aim to influence inflammation or symptom progression rather than regenerate lost neurons.
Cardiovascular disease is another major research area.
The heart has limited regenerative ability, and traditional therapies manage symptoms rather than repair tissue. This has driven significant interest in stem cell research.
In heart failure, studies have examined cardiac function, exercise tolerance, and quality-of-life metrics. Evidence is limited and evolving. Results have been mixed, with variability in cell survival, delivery methods, and clinical relevance. Stem cell therapy is not routine care for heart failure.
Following myocardial infarction, or heart attack, research explores timing of intervention, delivery techniques, and tissue signaling effects. Current applications remain investigational and are not standard post-heart-attack therapy.
Autoimmune and inflammatory conditions present a different challenge.
Here, the goal is often immune modulation rather than tissue replacement. These diseases are driven by immune dysfunction, outcomes are harder to measure, and risks can be higher.
Conditions frequently discussed include rheumatoid arthritis, lupus, Crohn’s disease, and multiple sclerosis. Evidence is condition-specific and often experimental. Specialist oversight is essential, and outcomes remain unpredictable.
It’s also important to address conditions that are commonly marketed but poorly supported by evidence.
These include broad anti-aging claims, generalized neurologic recovery promises, and systemic wellness treatments. These claims often rely on anecdotal reports rather than rigorous data, and patients should approach them with caution.
So why does evidence vary so widely?
Different tissues behave differently. Delivery feasibility varies by organ system. Pain is easier to measure than structural change. And long-term outcomes can take years to assess. These realities make broad, uniform claims inappropriate.
If you’re considering stem cell therapy, there are important questions to ask.
What evidence exists for your specific diagnosis?Is the treatment considered standard, investigational, or experimental?What outcomes are realistically measured?How does disease severity affect expectations?And what alternatives should be considered?
When evaluating a clinic, match claims to evidence levels. Avoid extrapolating results across conditions. Look for transparency about limitations. And prioritize individualized evaluation over generalized promises.
The takeaway is simple.
Stem cell therapy should be approached with condition-specific understanding, not broad assumptions. Evidence varies widely, and responsible care means aligning treatment discussions with what research actually supports.
Before we close, a brief disclaimer.
The information provided in this episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed - such as stem cell therapy, exosome therapy, platelet-rich plasma, or other biologic treatments - may be considered investigational or not FDA-approved for all conditions. Florida law requires disclosure of this status. While these procedures may be offered in accordance with applicable regulations, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of outcome is implied. All medical procedures involve potential risks, which should be discussed with your provider prior to treatment.
Thanks for listening to the STEMS Health Regenerative Medicine Podcast.We’ll see you next time.
 

Ep. 19 Joe Rogan Talks About Stem Cell Treatment in Mexico - So What’s the Case for Care in the U.S.?

To learn more about regenerative and restorative stem cell therapy treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
 
FULL TRANSCRIPT
Joe Rogan Talks About Stem Cell Treatment in Mexico - So What’s the Case for Care in the U.S.?
Welcome to the STEMS Health Regenerative Medicine Podcast.
In today’s episode, we’re addressing a topic that often comes up in popular media and online discussions: Joe Rogan talking about stem cell treatment in Mexico - and what that means for patients considering care in the United States.
Conversations about stem cell therapy don’t just happen in medical journals anymore. They show up in podcasts, social media, and personal stories shared by athletes, celebrities, and public figures. Joe Rogan has been one of the most influential voices bringing attention to stem cell treatment abroad, particularly in Mexico.
That visibility has helped raise awareness, especially among people frustrated by chronic pain, injuries, or slow recovery. But awareness alone doesn’t answer the most important question for patients: where is the safest and most appropriate place to receive care?
The answer isn’t simply Mexico or the United States. It’s about understanding tradeoffs, evidence, and accountability.
So let’s break this down clearly.
When Joe Rogan talks about stem cell therapy in Mexico, he’s usually pointing to a few consistent themes.
The first is access and speed. In many cases, biologic treatments are available more quickly outside the U.S., with fewer regulatory hurdles.
The second is personal stories. Rogan often references athletes or public figures who report improvement after treatment abroad.
And the third is frustration with bureaucracy. Like many patients, he has expressed skepticism about how long it can take for new medical approaches to become widely available in the United States.
These points resonate because they reflect real patient frustration. People dealing with pain or functional limitations often feel stuck between “nothing left to try” and “nothing approved yet.”
But when patients decide to seek treatment abroad, they’re making choices that involve more than access alone.
Medical tourism can offer options that aren’t widely available in the U.S., but it also comes with tradeoffs that aren’t always discussed.
Patients who go abroad may encounter different regulatory standards, less consistent outcome reporting, and limited long-term follow-up once they return home.
Many success stories shared publicly are anecdotal and short-term. They may reflect genuine individual experiences, but they don’t always show how a treatment performs across a broader patient population or over longer periods of time.
This doesn’t mean overseas care is inherently unsafe or ineffective. It does mean that patients should understand what protections, safeguards, and accountability structures may differ.
Now let’s talk about the case for stem cell care in the United States.
U.S.-based stem cell care is often described as conservative - and that conservatism can be frustrating. But it also reflects a system designed around accountability and patient protection.
Clinics operating in the U.S. are typically required to meet standards that include oversight by licensed physicians, formal informed consent that discloses when treatments are investigational, clear documentation of cell sourcing, handling, and delivery, and defined plans for follow-up care and complication management.
Another important factor is continuity of care. Receiving treatment close to home makes it easier to coordinate with primary care providers, specialists, physical therapists, and rehabilitation teams if issues arise.
For some patients, these safeguards outweigh the appeal of faster access.
At its core, Joe Rogan’s commentary highlights a real tension in modern medicine: regulation versus access.
Regulation can slow innovation and limit availability. But it also enforces standards around safety, advertising claims, and patient disclosure.
U.S. clinics are generally required to be more cautious in how they describe expected outcomes and risks. They’re held to stricter standards when it comes to documentation, informed consent, and claims made to patients.
So the real decision many patients face isn’t about geography. It’s about risk tolerance.
Some people prioritize speed and flexibility. Others prioritize structure, oversight, and recourse if something goes wrong.
Instead of asking, “Should I go to Mexico or stay in the U.S.?” a better set of questions might be:
Who is overseeing my care?What evidence exists for my specific condition?Is this treatment considered standard, investigational, or experimental?How are risks explained to me?And what follow-up care is available if problems arise?
These questions matter regardless of where a clinic is located.
Joe Rogan has played a role in bringing stem cell therapy into the public conversation, and that visibility has value. But podcast discussions - even thoughtful ones - are not a substitute for individualized medical guidance.
Stem cell therapy is complex, condition-specific, and still evolving. The best decisions happen when patients balance curiosity with caution, and when they prioritize evidence, transparency, and medical accountability over hype.
Education - not geography, and not celebrity endorsement - remains the most reliable guide.
Before we close, a brief disclaimer.
The information provided in this episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed - such as stem cell therapy, exosome therapy, or other biologic treatments - may be considered investigational or not FDA-approved for all conditions. Florida law requires disclosure of this status. While these procedures may be offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of outcome is implied. All medical procedures involve potential risks, which should be discussed with your provider prior to treatment.
Thanks for listening to the STEMS Health Regenerative Medicine Podcast.We’ll see you next time.
 

Ep. 18 Guide to Evaluating a Stem Cell Clinic

To learn more about regenerative and restorative stem cell therapy treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
FULL TRANSCRIPT - Guide to Evaluating a Stem Cell Clinic
Welcome to the STEMS Health Regenerative Medicine Podcast.
Today’s episode is a patient-education guide to evaluating a stem cell clinic - focused on due diligence, safety, and informed decision-making.
Stem cell therapy is increasingly discussed as an option in regenerative medicine, especially for joint pain, musculoskeletal injuries, and degenerative conditions. At the same time, clinics offering stem cell-based treatments can vary widely in medical oversight, transparency, and standards of care.
Our purpose today is not to promote treatment or discourage it. The goal is to help patients ask better questions, recognize red flags, and understand what responsible regenerative care should include.
Let’s start with why evaluating a clinic matters.
Stem cell therapy is not a single, standardized treatment. It can involve different cell sources, processing methods, delivery techniques, and regulatory pathways. And for many conditions, applications are still considered investigational.
Because of that, clinics may differ significantly in medical oversight, provider credentials, whether they participate in clinical trials, how they explain evidence, how they handle regulatory disclosures, how they price treatment, and what follow-up care they provide.
These differences directly affect patient safety, expectations, and outcomes. A careful evaluation helps patients distinguish between evidence-informed care and marketing-driven claims.
The first place to start is medical oversight and provider credentials.
A foundational question is simple: who is making the medical decisions?
Stem cell-based care should be overseen by licensed medical providers - typically physicians - who are responsible for evaluating the patient, diagnosing the condition, determining whether regenerative therapy is appropriate, performing or supervising procedures, and managing follow-up care and complications.
As a patient, you should be able to clearly identify the licensed physician directing care, confirm that provider’s state medical license, understand their clinical role and scope of practice, and know who performs evaluations versus who is handling administrative tasks.
Clinics operating primarily as wellness centers or sales organizations - rather than medical practices - may not provide the level of oversight appropriate for biologic therapies.
That leads to an important question: who is actually making clinical decisions?
Patients should clarify whether recommendations come from a licensed physician after an evaluation, or from non-clinical staff following preset protocols.
Red flags include treatment plans presented before medical evaluation, one-size-fits-all protocols applied to all patients, and sales consultations that replace physician visits.
Medical decisions should be made by clinicians, not by marketing or administrative teams.
Next, let’s talk about clinical trials and research context.
Some stem cell clinics participate in registered clinical trials. Others offer treatments that are informed by research but not part of a trial.
These are not the same thing, and clinics should clearly explain the difference.
Clinical trial registration can support transparency, ethical oversight, and defined outcome tracking. But not all legitimate care occurs within a trial setting.
What matters most is honest disclosure of where a treatment falls on the research-to-practice spectrum.
Patients can ask: is the clinic participating in a registered clinical trial? If so, where is it registered - such as ClinicalTrials dot gov? And does the clinic’s description match what the trial listing actually says?
It’s also important to understand that registration does not guarantee effectiveness. It only indicates that the treatment is being studied under defined conditions.
Now let’s address a common language trap: “research-based” versus “research-proven.”
These terms are often used interchangeably, but they mean very different things.
Research-based usually means a treatment is informed by scientific studies - often early-stage studies.
Research-proven suggests consistent clinical evidence and broader acceptance.
A responsible clinic should be willing to explain what level of evidence exists, what is still uncertain, and how that uncertainty is communicated to patients.
Next is published data and evidence transparency.
Not all stem cell applications have extensive published data, especially for emerging uses. That’s not automatically a problem - but how a clinic discusses evidence matters.
Patients should understand the difference between peer-reviewed studies, case reports or observational data, and testimonials or anecdotes.
Testimonials can reflect individual experiences. But they are not scientific evidence.
You don’t need to be a scientist to evaluate evidence more responsibly. You can ask basic questions: was the study peer-reviewed? How many patients were included? Were outcomes measured objectively? And is the condition studied actually similar to yours?
Clinics should be transparent when published data is limited and should avoid overstating conclusions.
Next is regulatory status and legal disclosures.
Many stem cell-based procedures are considered investigational for certain conditions. That does not automatically mean unsafe - but it does mean effectiveness has not been fully established.
Clinics are responsible for explaining whether a treatment is FDA-approved, cleared, or investigational - and what that status means for the patient.
A meaningful disclosure should clearly state the regulatory status, that outcomes cannot be guaranteed, and that research is still evolving.
Caution is warranted if a clinic claims a treatment is “FDA approved” without specifics, uses vague phrases like “FDA compliant” without explaining what that means, or minimizes or avoids discussion of regulatory status altogether.
Now let’s talk about the informed consent process.
Informed consent is not just a form. It’s a process.
Patients should receive enough information to understand what is being offered, what is known and unknown, what alternatives exist, and what risks are possible.
Consent should happen before payment, with time to review and ask questions.
A responsible consent process typically includes potential risks and side effects, the investigational nature of treatment if applicable, alternative treatment options, expected recovery and follow-up, and a clear statement that results are not guaranteed.
Warning signs include pressure to sign the same day, oversimplified consent forms, or language that minimizes uncertainty or risk.
Patients should feel informed - not rushed.
Next is pricing transparency and financial practices.
Stem cell therapy pricing can vary widely based on cell source, processing, delivery method, and follow-up care.
Patients should understand what is included in the quoted price, what may cost extra - like imaging, follow-up visits, or repeat treatments - and the refund, cancellation, or rescheduling policies.
Key questions include: does pricing include evaluation and follow-up care? Are additional treatments expected or optional? And are financing arrangements involved?
Financial red flags include guaranteed results tied to payment, discounts for immediate commitment, or requests for payment before medical evaluation.
Next is follow-up care and outcome monitoring.
Follow-up is a core component of responsible regenerative medicine.
Patients should ask how often follow-up will occur, who to contact with concerns, how outcomes and complications are tracked, and whether licensed providers are available after treatment.
Follow-up care should reasonably include scheduled check-ins, monitoring for side effects or complications, and guidance on activity, rehabilitation, and recovery.
Clinics should also clearly explain how unexpected issues are handled, and how care is coordinated with a patient’s other healthcare providers if needed.
Now let’s address marketing claims and guarantees.
Stem cell therapy involves biologic variability, which means outcomes cannot be guaranteed.
Be cautious of clinics that use words like “cure” or “permanent fix,” apply the same claims to unrelated conditions, or present testimonials as proof.
Clear, educational language is generally a sign of transparency. Absolute claims are not.
So here’s a practical due-diligence checklist.
Before choosing a stem cell clinic, consider whether it provides licensed medical oversight, clear explanation of cell source and handling, honest discussion of evidence and uncertainty, regulatory and investigational disclosures, meaningful informed consent, transparent pricing, and a defined follow-up care plan.
The big takeaway is this.
Stem cell therapy should be approached as a medical process - not a consumer product. Details matter: evaluation, sourcing, handling, delivery, and follow-up.
This guide is meant to support thoughtful conversations with licensed providers and help patients make decisions grounded in evidence, transparency, and individual suitability.
Before we close, a brief disclaimer.
The information provided in this episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed - such as stem cell therapy, exosome therapy, or other biologic treatments - may be considered investigational or not FDA-approved for all conditions. Florida law requires disclosure of this status. While these procedures may be offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of outcome is implied. All medical procedures involve potential risks, which should be discussed with your provider prior to treatment.
Thanks for listening to the STEMS Health Regenerative Medicine Podcast.We’ll see you next time.
 

Ep. 17 Guide to How Stem Cell Therapy Works

To learn more about regenerative and restorative stem cell therapy treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
 
FULL TRANSCRIPT
Welcome to the STEMS Health Regenerative Medicine Podcast.
In today’s episode, we’re taking a clear, step-by-step look at how stem cell therapy actually works in real clinical settings. Not as a single treatment, not as a promise - but as a medical workflow.
Stem cell therapy is often discussed as one idea, but in practice it’s a multi-step process. Outcomes are influenced not just by the cells themselves, but by how those cells are sourced, handled, delivered, and how the body responds afterward.
The goal of this episode is education. We’ll walk through the full process in plain language - from evaluation and sourcing, to lab handling, delivery, and what happens inside the body - without overpromising results.
Let’s begin with what “stem cell therapy” means in practical terms.
In clinical care, stem cell therapy refers to the use of biologic cells or cell-derived materials as part of a regenerative treatment plan. That plan may involve different cell sources, processing methods, and delivery routes depending on the condition being addressed.
Importantly, stem cell therapy is not a single standardized treatment. Two patients may both be described as receiving stem cell-based care, yet their workflows - from sourcing to delivery - may be very different.
Understanding those differences helps patients ask informed questions and better interpret clinic claims.
Now let’s walk through the typical workflow.
Step one is patient evaluation and treatment planning.
Before any discussion of cells, regenerative care begins with a medical evaluation. Clinicians assess whether stem cell-based approaches are being considered and whether a patient may be an appropriate candidate.
This evaluation usually includes a review of medical history and current medications, a physical exam focused on pain, mobility, and function, imaging such as X-ray, MRI, or ultrasound when appropriate, and discussion of prior treatments and how the patient responded.
The goal is not to sell a therapy. It’s to understand the underlying problem. Structural damage, inflammation, and degenerative changes can behave very differently - even when symptoms look similar.
Baseline measurements like pain scores, range of motion, and activity limitations are often documented so progress can be evaluated over time.
Stem cell therapy is most often discussed for musculoskeletal concerns such as joint pain, tendon or ligament injuries, and certain spine-related conditions. Clinicians also screen for situations where regenerative therapies may not be appropriate, such as active infection, systemic illness, or conditions requiring immediate surgery.
Imaging matters here. Ultrasound, in particular, allows clinicians to visualize soft tissues and joints in real time and helps guide accurate delivery when injections are used.
Step two is stem cell sourcing - where the cells come from.
Broadly, stem cells fall into two categories based on origin: autologous and allogeneic.
Autologous stem cells come from the patient’s own tissue. Common sources include bone marrow and adipose, or fat tissue. These tissues contain adult stem cells along with supportive cells.
Because the cells come from the patient, compatibility concerns are minimized. Autologous workflows often occur on the same day, where cells are collected, processed, and delivered during a single visit, depending on protocol.
From a patient’s perspective, this step is best understood as a collection process rather than surgery. Clinicians explain what to expect during consultation.
Allogeneic stem cells come from screened donors. These cells are processed and stored according to established standards before being distributed for clinical or research use.
Donor screening, testing, and documentation are central to this approach. Allogeneic products may be considered when standardization, availability, or logistics are prioritized.
Regardless of source, clinics should clearly explain whether cells are patient-derived or donor-derived, and why that source is being considered.
Chain of custody is also important. This refers to tracking and documentation of biologic material from collection through delivery, supporting safety, traceability, and accountability.
Step three is laboratory processing and handling.
After sourcing, cells undergo processing. Processing doesn’t mean the same thing everywhere. It can range from minimal preparation to more complex lab workflows conducted in regulated environments.
At a high level, processing prepares biologic material for safe and consistent delivery.
Cell isolation separates specific cellular components from collected tissue. Concentration increases the proportion of target cells in a sample. These steps help standardize what is delivered, rather than injecting raw tissue.
Quality controls - such as viability checks, sterility practices, and time and temperature controls - play a major role in safety and consistency, even though patients don’t usually see them.
In some workflows, biologic material is used the same day. In others, it may be stored through cryopreservation, or controlled freezing, for later use. Proper storage requires careful handling to maintain cell quality.
Step four is delivery into the body.
Delivery refers to how and where biologic material is introduced. The route is chosen based on the tissue being treated and the clinical goal.
For many musculoskeletal conditions, delivery involves targeted injection into a joint or soft-tissue structure, often guided by ultrasound. From a patient standpoint, this is similar to other image-guided injections, with brief discomfort and post-procedure activity guidance.
Some protocols use intravenous, or IV, infusion instead of local injection. IV delivery introduces biologic material into the bloodstream for systemic circulation.
Local injections aim to place material directly at the target tissue. IV approaches rely more on broader biologic signaling. The choice depends on clinical rationale - not a one-size-fits-all rule.
Step five is what happens after delivery.
One of the most common questions patients ask is whether stem cells turn into new tissue. In reality, regenerative responses involve multiple mechanisms.
Research generally focuses on direct cellular activity and indirect signaling effects.
Homing refers to the tendency of cells or signals to localize toward areas of injury or inflammation. Damaged tissues release chemical cues that differ from healthy tissue.
The tissue microenvironment - factors like oxygen levels, blood supply, inflammation, and mechanical stress - plays a major role in how biologic material behaves.
Paracrine signaling is another key concept. Rather than becoming replacement tissue, delivered cells may release substances that influence nearby cells.
A common analogy is a foreman at a repair site. Instead of doing all the work, the foreman sends instructions that guide others. In regenerative medicine, signaling molecules may influence inflammation, cellular behavior, and tissue response.
Immunomodulation is also studied. This refers to influencing immune responses toward balance rather than suppression, which may relate to symptom changes such as pain or stiffness.
Cells also release extracellular vesicles - microscopic packages carrying proteins and genetic material. Angiogenesis, or support for new blood vessel formation, is another area of active research. These mechanisms remain under investigation rather than guaranteed outcomes.
Step six is healing timeline and follow-up.
Regenerative processes are not immediate. Patients are often advised that changes may occur gradually over weeks or months.
Early changes may include temporary soreness or inflammation from the procedure itself. Later changes may involve gradual improvements in comfort or function, depending on many factors.
Follow-up appointments allow clinicians to compare progress against baseline measurements. In some cases, physical therapy or guided rehabilitation is recommended to support recovery.
Outcomes may be influenced by condition severity and duration, overall health, activity modification, rehabilitation adherence, and tissue type involved.
As with any medical procedure, stem cell-based therapies carry risks, including infection, bleeding, localized pain, or inflammatory flare. Screening, sterile handling, and informed consent aim to reduce these risks.
Patients are encouraged to ask detailed questions about sourcing, processing, delivery, and follow-up expectations.
Because regenerative medicine is evolving, claims can vary widely. Practical signs of transparent care include clear explanation of cell source, defined handling and delivery methods, realistic goals instead of guarantees, and willingness to discuss limitations.
Stem cell therapy is best understood as a process - not a single event. From evaluation and sourcing to lab handling, delivery, and post-treatment biology, each step plays a role in how the body responds.
Understanding this workflow gives patients a clearer framework for evaluating regenerative care options and having informed conversations with licensed providers.
Before we close, a brief disclaimer.
The information provided in this episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed - such as stem cell therapy, exosome therapy, or other biologic treatments - may be considered investigational or not FDA-approved for all conditions. Florida law requires disclosure of this status. While these procedures may be offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of outcome is implied. All medical procedures involve potential risks, which should be discussed with your provider prior to treatment.
Thanks for listening to the STEMS Health Regenerative Medicine Podcast.We’ll see you next time.
 

Ep. 16 Guide to Stem Cell Therapy Basics

To learn more about regenerative and restorative stem cell therapy treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
 
FULL Transcript
Welcome to the STEMS Health Regenerative Medicine Podcast.
In this episode, we’re walking through a practical, step-by-step guide to how stem cell therapy actually works - from initial evaluation, to cell sourcing, to delivery, and finally to what happens inside the body afterward.
Stem cell therapy is often discussed as a single idea. But in real clinical settings, it’s a multi-step medical workflow. Outcomes are influenced not just by the cells themselves, but by how those cells are sourced, handled, delivered, and how the body responds over time.
The goal of this episode is education - not promotion. We’ll explain each step in plain language, without overpromising results, so patients can better understand the process and evaluate regenerative care claims more accurately.
Let’s start by clarifying what “stem cell therapy” means in practical terms.
In clinical use, stem cell therapy refers to the use of biologic cells - or cell-derived materials - as part of a regenerative care plan. That plan may involve different cell sources, processing methods, and delivery routes depending on the condition being addressed.
Importantly, stem cell therapy is not a single standardized treatment. Two patients may both be described as receiving stem cell-based care, yet their workflows - from sourcing to delivery - can differ substantially.
Understanding those differences helps patients ask better questions and interpret claims with more clarity.
Now let’s walk through the typical workflow, step by step.
Step one is patient evaluation and treatment planning.
Before any discussion of cells, regenerative care begins with a medical evaluation. Clinicians assess whether stem cell-based approaches are even being considered, and whether a patient may be an appropriate candidate.
This evaluation typically includes a review of medical history and current medications, a physical examination focused on pain, mobility, and function, imaging studies such as X-ray, MRI, or ultrasound when appropriate, and discussion of prior treatments and how the patient responded to them.
The goal is not to sell a therapy, but to understand the underlying problem. Structural damage, inflammation, and degenerative changes can behave very differently, even when symptoms appear similar.
Baseline measurements - such as pain scores, range of motion, or activity limitations - are often documented so changes can be evaluated over time.
Stem cell therapy is most commonly discussed for musculoskeletal concerns like joint pain, tendon or ligament injuries, and certain spine-related conditions. These discussions focus on tissue quality, inflammation, and function, rather than a diagnosis alone.
Clinicians also screen for situations where regenerative therapies may not be appropriate, such as active infection, certain systemic illnesses, or conditions requiring immediate surgical intervention.
Imaging plays an important role here. Ultrasound, in particular, allows clinicians to visualize soft tissues and joints in real time. When injections are used, ultrasound guidance helps confirm accurate placement and provides documentation of where biologic material is delivered.
Step two is stem cell sourcing - where the cells come from.
Broadly, stem cells fall into two categories based on origin: autologous and allogeneic.
Autologous stem cells come from the patient’s own tissue. Commonly discussed sources include bone marrow and adipose, or fat tissue. These tissues contain populations of adult stem cells along with supportive cells.
Because the cells originate from the patient, compatibility concerns are minimized. Autologous workflows often occur on the same day, where cells are collected, processed, and delivered during a single visit, depending on the protocol.
From the patient’s perspective, this step is best understood as a collection process rather than surgery. Specifics vary, and clinicians explain what to expect during consultation.
Allogeneic stem cells, on the other hand, are derived from screened donors. These cells are processed and stored according to established standards before being distributed for clinical or research use.
Donor screening, testing, and documentation are central to this approach. Allogeneic products may be considered when standardization, availability, or logistical factors are prioritized.
Regardless of source, clinics should be transparent about whether cells are patient-derived or donor-derived, and why a particular option is being discussed.
Chain of custody matters at this stage. This refers to tracking and documentation of biologic material from collection through delivery. Proper labeling, handling, and record-keeping support safety, traceability, and accountability.
Step three is laboratory processing and handling.
After sourcing, cells undergo processing. Processing doesn’t mean the same thing everywhere. It can range from minimal preparation to more complex laboratory workflows performed in regulated environments.
At a high level, processing prepares biologic material for safe and consistent delivery.
Cell isolation involves separating specific cellular components from collected tissue. Concentration refers to increasing the proportion of target cells within a sample. These steps help standardize what is delivered, rather than injecting raw tissue.
Quality control measures - such as viability checks, sterility practices, and time and temperature controls - play a central role in safety and consistency, even though patients rarely see them directly.
In some workflows, biologic material is used the same day. In others, it may be stored through cryopreservation, or controlled freezing, for later use. Proper storage requires traceability and careful handling during thawing to preserve cell quality.
Step four is delivery into the body.
Delivery refers to how and where biologic material is introduced. The route is chosen based on the tissue being addressed and the clinical goal.
For many musculoskeletal conditions, delivery involves targeted injection into a joint or soft-tissue structure, often using ultrasound guidance. From a patient standpoint, this is similar to other image-guided injections, with brief discomfort and post-procedure activity instructions.
Some protocols use intravenous, or IV, infusion instead of local injection. IV delivery introduces biologic material into the bloodstream, allowing systemic circulation.
Local injections aim to place material directly at a target tissue. IV approaches rely more on biologic signaling and systemic distribution. The choice depends on clinical rationale - not a one-size-fits-all rule.
Step five is what happens after delivery.
One of the most common questions patients ask is whether stem cells “turn into new tissue.” In reality, regenerative responses involve multiple mechanisms.
Research generally focuses on both direct cellular activity and indirect signaling effects.
Homing refers to the tendency of cells or signals to localize toward areas of injury or inflammation. Damaged tissues release chemical cues that differ from healthy tissue.
The tissue microenvironment - factors like oxygen levels, blood supply, inflammation, and mechanical stress - plays a major role in how biologic material behaves after delivery.
Paracrine signaling is another key concept. Rather than becoming replacement tissue, delivered cells may release substances that influence nearby cells.
A common analogy is a foreman on a repair site. Instead of doing every repair directly, the foreman sends instructions that guide other workers. In regenerative medicine, signaling molecules may influence inflammation, cellular activity, and tissue response.
Immunomodulation is also studied. This refers to influencing immune responses toward balance rather than suppression. These interactions may relate to symptom changes such as pain or stiffness, depending on individual biology and condition severity.
Cells also release extracellular vesicles - microscopic packages containing proteins and genetic material that can influence nearby cells. Angiogenesis, or support for new blood vessel formation, is another area of research. These mechanisms remain under investigation rather than guaranteed outcomes.
Step six is healing timeline and follow-up.
Regenerative processes are not immediate. Patients are often advised that changes may occur gradually over weeks or months.
Early changes may include temporary soreness or inflammation related to delivery. Later changes may involve gradual improvements in comfort or function, depending on many factors.
Follow-up appointments allow clinicians to assess progress relative to baseline measurements. In some cases, physical therapy or guided rehabilitation is recommended to support recovery.
Factors influencing outcomes include condition severity and duration, overall health, activity modification, rehabilitation adherence, and tissue type involved.
As with any medical procedure, there are risks. These may include infection, bleeding, localized pain, or inflammatory flare. Screening, sterile handling, and appropriate patient selection aim to reduce these risks.
Clinics are responsible for informed consent, accurate documentation, and avoiding unsupported claims. Patients should feel encouraged to ask detailed questions at every step.
When evaluating stem cell claims, practical indicators of transparent care include clear explanation of cell source, defined handling and delivery methods, realistic goals rather than guarantees, and willingness to discuss limitations.
Stem cell therapy is best understood as a process - not a single event. From evaluation to sourcing, lab handling, delivery, and post-treatment biology, each step plays a role in how the body responds.
Understanding this workflow gives patients a clearer framework for evaluating regenerative care and engaging in informed conversations with licensed providers.
Before we close, a brief disclaimer.
The information provided in this episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed - such as stem cell therapy, exosome therapy, or other biologic treatments - may be considered investigational or not FDA-approved for all conditions. Florida law requires disclosure of this status. While these procedures may be offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of outcome is implied. All medical procedures involve potential risks, which should be discussed with your provider prior to treatment.
Thanks for listening to the STEMS Health Regenerative Medicine Podcast.We’ll see you next time.
 

Ep 15 Dr. Mari Dezawa — MUSE Cell Innovations Founder and CSO

A profile of Dr. Mari Dezawa, whose discovery of MUSE Cells reshaped how regenerative medicine understands stress-enduring, pluripotent-like cells and their potential to support targeted joint and spine repair.
To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
FULL TRANSCRIPT
Dr. Mari Dezawa is one of the most influential figures in modern regenerative medicine. As Chief Scientific Officer of MUSE Cell Innovations and a professor at Tohoku University in Japan, she has reshaped the field through her groundbreaking discovery of MUSE Cells - multilineage-differentiating stress-enduring cells.
Her work has provided a safer, more targeted alternative to embryonic and induced pluripotent stem cells, without the associated ethical or safety concerns. MUSE Cells are now at the center of a growing number of therapies focused on orthopedic and spine-related repair.
So what exactly are MUSE Cells, and why do they matter?
MUSE Cells are a rare type of adult stem cell found in bone marrow and umbilical cord tissue. They make up only one to two percent of mesenchymal stem cells, but they exhibit extraordinary properties. They survive harsh cellular stress. They can differentiate into all three germ layers - just like pluripotent cells. And most importantly, they do not form tumors.
These characteristics are what make MUSE Cells so valuable. They offer the potential to regenerate tissue in a highly controlled way while reducing safety risks that have long slowed the adoption of stem cell-based treatments.
One of the keys to understanding MUSE Cells is their identification. Dr. Dezawa’s team isolated them using a specific surface marker called SSEA-3. These cells can endure conditions that would destroy most other cells, and that’s where their name comes from: stress-enduring.
They’ve been shown to differentiate into cell types across the ectodermal, mesodermal, and endodermal lines, supporting tissues ranging from nerve to muscle to cartilage. But unlike embryonic stem cells or iPSCs, they do so without forming teratomas or requiring genetic manipulation.
So how do they work in practice?
One of the most important clinical features of MUSE Cells is their ability to home to sites of injury. Whether delivered locally or systemically, they seek out damaged or inflamed tissue. Once there, they can either integrate and differentiate, or secrete beneficial factors that reduce inflammation and support surrounding cells.
This is particularly relevant in orthopedic and spine care. Studies suggest MUSE Cells may support healing in the knees, hips, shoulders, and spine - areas where tissue damage is often slow to repair. Instead of simply reducing inflammation, they offer cellular-level restoration.
This precision is what separates MUSE therapy from more traditional mesenchymal stem cell approaches. Where bulk MSCs may function broadly and non-specifically, MUSE Cells target the exact areas where healing is most needed, bringing structural support and regenerative signals.
Dr. Dezawa’s work has moved beyond the lab and into clinical care. Through her partnership with MCI - Muse Cell Innovations - licensed providers are now offering MUSE Cell therapy in orthopedic settings. One such provider is STEMS Health in Miami Beach, one of only a few Florida clinics authorized to administer authentic Dezawa MUSE Cells.
Treatments focus on joint and spine injections guided by ultrasound. No IV infusions are offered. Instead, therapy is highly localized, and delivered in a way that aligns with the scientific properties of the cells.
As Chief Scientific Officer, Dr. Dezawa continues to lead the advancement of MUSE Cell research. Her team is working on GMP-compliant production lines, large-scale validation studies, and peer-reviewed research exploring how these cells can benefit not just orthopedics, but neurology, immunology, and more.
Her legacy is still in progress. But what’s clear is that Dr. Mari Dezawa has introduced a new level of precision, safety, and therapeutic potential into regenerative medicine.
Here are a few quick answers to common questions.
What makes Dr. Dezawa’s discovery unique? She identified a subset of adult stem cells with pluripotent-like behavior that can aid tissue repair without the risks associated with iPSCs or embryonic stem cells.
Are MUSE Cells safer than traditional pluripotent stem cells? Yes. MUSE Cells are non-tumorigenic and do not require genetic reprogramming, offering a more stable path to therapeutic use.
Do they replace traditional MSCs? No. They complement them. MUSE Cells offer greater targeting and regenerative endurance, but MSCs remain useful in broader applications.
Can they treat spine and joint issues? Current clinical use includes orthopedic pain, joint degeneration, and post-injury soft tissue recovery in the spine, knee, and shoulder.
Where can patients access MUSE Cell therapy? STEMS Health in Miami Beach is one of the few clinics in Florida licensed to provide authentic Dezawa MUSE Cell treatment for orthopedic conditions.
Thanks for listening.
---
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 14 Adult Stem Cells for Advanced Dry Macular Degeneration

A look at emerging clinical research showing how adult stem cell transplantation may offer early visual improvements and a new therapeutic pathway for patients with advanced dry AMD and geographic atrophy.
To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.FULL TRANSCRIPT
Dry age-related macular degeneration, also known as dry AMD, is one of the most common causes of irreversible vision loss in adults over 65. Its advanced form, called geographic atrophy, leads to the progressive breakdown of retinal cells and has few effective treatment options.
Unlike wet AMD, which can be managed with injections, advanced dry AMD lacks therapies that can restore lost vision. This has created an urgent need for new solutions - and that’s where adult stem cells may come in.
Emerging research suggests that adult stem cell transplantation could offer a new path forward. Rather than simply slowing disease progression, stem cell therapies are being studied for their ability to support visual function and preserve retinal structure.
Let’s take a closer look at why adult stem cells are drawing so much interest in this area.
Adult stem cells, including mesenchymal stem cells and retinal progenitor cells, are known for their anti-inflammatory and immune-modulating properties. They can be ethically sourced from bone marrow or umbilical tissue and do not carry the tumor risks associated with embryonic or pluripotent stem cells.
In animal models, these cells have been shown to preserve photoreceptors, reduce inflammation in the eye, and even improve visual responses. This laid the groundwork for early human trials.
Several small, early-phase clinical studies have explored subretinal injections of these cells in patients with geographic atrophy. So far, results are cautiously optimistic. Most trials have reported no serious safety issues. And in some cases, participants experienced modest improvements in visual acuity or contrast sensitivity over the course of 6 to 12 months.
Imaging studies have also shown stabilization in areas of retinal atrophy, suggesting the potential for real biological impact.
How do these cells work?
One mechanism is paracrine signaling - where the transplanted cells don’t necessarily become new retinal cells, but instead release beneficial signals. These may enhance the survival of photoreceptors, protect the retinal pigment epithelium, and regulate inflammation. In some cases, retinal progenitor cells may even integrate into retinal layers and contribute to structural repair.
The preferred method of delivery is subretinal injection, placing the cells directly into the space between the retina and its supporting layer. This ensures close contact with damaged tissue while minimizing systemic exposure and the risk of unwanted cell migration.
Innovations like image-guided microinjections have improved safety and precision in these procedures, reducing the risk of complications.
Of course, stem cell therapy isn’t without its challenges.
Ensuring consistent quality and viability of cell batches - especially for off-the-shelf or donor-based products - is critical. Long-term durability of the benefits is still being studied. And researchers are working to identify reliable biomarkers to track whether the therapy is truly working.
Most trials now include rigorous visual testing, OCT imaging, and biomarker analysis over one to two years. Regulatory agencies, including the FDA, require this kind of detailed validation before allowing stem cell therapies to move into broader use.
So what comes next?
Larger phase 2 trials are now underway, aiming to confirm the early signals seen in smaller studies. Some research is exploring combination approaches - pairing stem cells with gene therapies or drugs that target other parts of the disease pathway. Others are looking at personalized stem cell lines for use in high-risk individuals.
And with the help of AI-assisted retinal imaging, physicians may soon be able to detect changes earlier and tailor treatment more precisely to each patient.
While stem cells for dry AMD are still investigational, their potential is significant. For patients with few existing options, they represent a new frontier in vision care - one focused not just on slowing loss, but on supporting real regeneration.
Here are a few frequently asked questions.
Are stem cells currently FDA-approved for dry AMD? No. These therapies are still being studied and are not yet approved for routine clinical use.
How are the cells delivered? Most studies use subretinal injection, placing the cells directly behind the retina near areas of damage.
Can stem cells actually improve vision? Some trials have shown improvements in vision and retinal structure, but larger studies are needed to confirm these effects.
Are there any risks? Like any eye surgery, there are risks, including infection, inflammation, or retinal detachment. Most events so far have been mild.
What’s next in research? Researchers are studying which cell types, doses, and delivery methods work best - and how long benefits might last.
Thanks for listening.
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 13 FDA’s Evolving Pipeline of iPSC and MSC Products

An overview of how new FDA clearances for iPSC-derived and MSC-based therapies indicate growing regulatory maturity, clearer translational pathways, and expanding commercialization potential for next-generation cell products.
To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
 
FULL TRANSCRIPT
 
Regenerative medicine is moving into a new era. Once dominated by experimental applications and regulatory gray zones, today’s landscape is defined by FDA-cleared products, structured trial pathways, and tighter manufacturing oversight.
At the center of this shift are cell-based therapies built around two core technologies: induced pluripotent stem cells, or iPSCs, and mesenchymal stem cells, or MSCs.
The FDA has already cleared dozens of therapies using or related to these cell types. This includes products like Ryoncil for pediatric graft-versus-host disease, Allocord for hematologic disorders, and MACI, used to treat cartilage injuries in the knee.
These approvals signal something bigger: regulatory maturity. The FDA is actively shaping pathways to clinical use - through formal guidance, standardized testing, and accelerated programs like the Regenerative Medicine Advanced Therapy designation.
Let’s break down how iPSC and MSC therapies differ and why they’re so important.
iPSCs are adult cells that have been reprogrammed to act like embryonic stem cells. They can become nearly any type of cell - cardiac, neural, retinal, and more. This flexibility makes them ideal for targeted cell replacement therapies, especially in complex diseases like macular degeneration or Parkinson’s.
MSCs, by contrast, are naturally multipotent. Found in bone marrow, fat, and umbilical cord tissue, these cells don’t require genetic engineering. They’re known for their ability to modulate the immune system, reduce inflammation, and support tissue repair. That makes them particularly valuable in orthopedics and inflammatory conditions.
While MSCs are more common in current FDA approvals, iPSCs are gaining ground. Early-phase trials are evaluating iPSC-derived retinal cells, cardiomyocytes, and nerve-supporting cells. Many gene and cell therapies now in development incorporate iPSC technology behind the scenes.
The FDA’s Center for Biologics Evaluation and Research, or CBER, has taken several steps to support these innovations. This includes guidance documents covering everything from potency testing and donor screening to good manufacturing practices.
Under FDA regulations, both iPSC and MSC therapies must meet strict standards before they reach patients. That means proving cell identity, biological potency, safety, and sterility.
Manufacturers are required to run viability assays, confirm genetic stability, test for contamination, and operate in certified GMP labs. For iPSCs, the risk of uncontrolled growth or tumor formation requires even more scrutiny.
But regulatory clarity is only part of the story. The commercial landscape is also evolving.
We’re seeing an increase in off-the-shelf allogeneic products like Ryoncil, which offer scalable access to care without requiring a custom donor for every patient. Combination therapies - pairing cells with scaffolds or delivery devices - are also becoming more common, especially in orthopedics.
Another shift is happening in clinical access. Decentralized trial networks are expanding the reach of investigational therapies. Patients who don’t live near a major academic center may still be eligible to participate in early access programs.
Altogether, these developments suggest that cell-based therapies are moving from niche to mainstream.
For patients, this means more options and a clearer understanding of what’s available - and what’s still being studied. For providers, it means better tools, more data, and the chance to align treatment with individual patient biology.
Let’s wrap up with a few key questions.
What’s the difference between iPSC and MSC therapies? iPSCs are reprogrammed to become nearly any cell type and are often used in precise replacement therapies. MSCs are naturally multipotent and valued for immune modulation and tissue repair, especially in orthopedic use.
Are any iPSC-based therapies FDA-approved? Most FDA-cleared therapies currently involve MSCs or related platforms. iPSC-based products are primarily in trial phases but are moving closer to approval.
What is RMAT designation? The FDA’s Regenerative Medicine Advanced Therapy designation offers fast-track support for promising cell therapies showing early clinical benefit.
How are these products manufactured safely? They must meet strict FDA standards for identity, potency, sterility, and safety - and must be produced in certified GMP-compliant facilities.
What are today’s top uses for MSC therapies? MSCs are widely used for joint pain, cartilage injuries, graft-versus-host disease, and increasingly for autoimmune and cardiovascular issues.
Thanks for listening.
-------------------
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 12 Umbilical Cord-Derived Muse Cells: A Cleaner, Smarter Source for Regeneration

Unlike adipose or bone-derived cells, Dezawa MUSE Cells come from screened umbilical cord tissue - delivering consistency, purity, and clinical-grade potency for orthopedic repair.
To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
FULL TRANSCRIPT 
Stem cell therapy is evolving, and not all stem cells are created equal. At STEMS Health, one key differentiator is the source. While many clinics use fat or bone marrow to extract stem cells, we’ve chosen a cleaner and more consistent path - umbilical cord-derived MUSE Cells.
These cells offer clinical-grade purity, younger biological age, and stronger regenerative potential, particularly in orthopedic care. Let’s explore why this matters and how it impacts real-world outcomes for patients.
Most people don’t realize that stem cells can be harvested from multiple tissues. Fat, bone marrow, and umbilical cord tissue are all common sources. But when it comes to precision, safety, and reproducibility, umbilical cord tissue offers distinct advantages.
Dezawa MUSE Cells are extracted from screened, donated umbilical cords. These cells are part of a rare subpopulation known for their stress endurance, their ability to home to damaged tissue, and their advanced communication with surrounding cells. That makes them especially well-suited for joint and spine therapies.
One of the biggest advantages of umbilical cord tissue is its biological youth. These cells are fresher, more potent, and have higher telomerase activity than cells taken from older adults. They also respond better to the bio-signaling that drives tissue healing.
Collection is non-invasive and ethically performed with full donor consent. All donor tissue is rigorously screened for infections, genetic issues, and other risk factors. That ensures each batch of cells is sterile, safe, and consistent in its performance.
This is not always the case with stem cells from fat or bone marrow. In those cases, the patient’s age, chronic illness, or medications can impact the number and quality of viable cells. Harvesting those cells can also involve invasive procedures and longer recovery times.
By contrast, cord-derived MUSE Cells are cryopreserved and ready for use. Their consistency means we can offer higher standards of care with more predictable outcomes.
Let’s talk about where and how we use these cells at STEMS Health.
We focus exclusively on orthopedic applications - specifically the knee, shoulder, and spine. That includes early-stage arthritis, cartilage wear, rotator cuff injuries, and degenerative spine conditions like disc inflammation or facet joint pain.
Our procedures are outpatient and image-guided, using ultrasound or fluoroscopy to ensure precise delivery. There’s no general anesthesia, and most patients resume activity within a few days.
So what makes these cells work?
First, they naturally migrate to the site of injury or inflammation. Once there, they help modulate the immune response, reduce inflammatory markers, and promote tissue regeneration. Their youthful biology means they stay viable longer and respond more effectively in difficult environments like low-oxygen or high-stress joints.
Second, these cells are active participants in the body’s signaling systems. They help support collagen production, improve soft tissue integrity, and enhance the stability of joints over time.
At STEMS Health, our focus is always on safe, ethical, and licensed care. We’re proud to be one of only a few clinics in Florida licensed by MCI - Muse Cell Innovations - to offer authentic Dezawa MUSE Cell therapy.
We do not use unverified products or advertise off-label uses like IV infusion. Everything we do is supported by imaging, diagnostic review, and personalized aftercare.
Let’s wrap up with a few frequently asked questions.
Are cord-derived MUSE cells safe? Yes. They’re ethically sourced, lab screened, and processed under clinical-grade conditions. They meet strict standards for orthopedic use.
Why not use fat or bone marrow stem cells? Those are still used in medicine, but they’re less consistent. Cord-derived MUSE cells offer cleaner sourcing, higher potency, and eliminate the need for invasive harvesting.
How is the therapy delivered? Cells are injected directly into the joint or spinal region using advanced imaging guidance. The procedure is brief and requires no hospitalization.
What can I expect after treatment? Many patients experience reduced pain and improved joint function over time. Results vary, but most people return to normal activity quickly.
Thanks for listening.
-------------------
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 11 Musecell Innovations Dezawa Cells vs. Traditional Stem Cell Therapy: The Science Behind Muse Cells

Discover how MU cells—just 1–2% of MSCs—deliver greater regenerative potential, making them the premium choice for joint and spinal recovery.
To learn more about regenerative and restorative treatments, visit stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.
FULL TRANSCRIPT
 
Not all stem cells are created equal. While mesenchymal stem cells, or MSCs, have been used in orthopedic therapy for years, a more refined approach is now available - one that offers greater precision and regenerative intelligence. These are MUSE Cells.
MUSE stands for Multilineage-differentiating Stress-Enduring cells. First discovered by Dr. Mari Dezawa, MUSE cells are a rare, naturally occurring subset of MSCs that can survive in harsh environments, migrate to injured tissue, and help rebuild damaged structures through advanced signaling.
What makes them unique is their rarity and specificity. Only one to two percent of a typical MSC sample contains MUSE cells. Isolating and using this elite group of cells allows for more focused, reliable results - especially in orthopedic applications.
Now to be clear, traditional MSCs remain useful in many therapies. They’re widely studied and offer benefits when applied correctly. But MUSE cells take that foundation and sharpen it - giving us a targeted tool for treating complex joint and spine conditions.
At STEMS Health in Miami Beach, we’ve seen this evolution firsthand. Our clinic focuses on using Dezawa MUSE Cells specifically for orthopedic pain and soft tissue injuries - conditions like knee arthritis, rotator cuff tears, and degenerative disc disease.
Because MUSE cells are naturally drawn to areas of inflammation or damage, they don’t just sit in the joint space. Once injected - under precise image guidance - they begin working to regulate inflammation, promote structural support, and encourage collagen and cartilage repair.
This makes them ideal for patients who may not be ready for surgery but need more than temporary relief from cortisone or physical therapy.
Unlike general MSC therapies, which may vary in cell count or quality depending on how they’re harvested, MUSE cells used at STEMS Health come from screened, umbilical cord-derived sources. These cells are biologically younger and processed in cleanroom labs under strict compliance standards.
There’s no guesswork. Each batch is traceable, purified, and prepared with orthopedic application in mind.
Treatments are performed in-office. They do not require general anesthesia, and most patients return to their routines within a few days. Results vary, but many report improved mobility, pain reduction, and greater joint stability over time.
Importantly, STEMS Health does not offer IV-based stem cell therapy or advertise unregulated uses. We focus exclusively on orthopedic cases and follow Florida’s formal legal framework for regenerative medicine. In fact, we’re one of just a few clinics in the state licensed to administer MUSE Cell therapy through our partnership with MCI - Muse Cell Innovations.
If you’ve struggled with joint pain, tendon injuries, or spinal inflammation - and traditional options haven’t provided lasting relief - this next-generation approach may be worth exploring.
Thanks for listening.
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.
Certain regenerative medicine procedures discussed—such as stem cell therapy, exosome therapy, or other biologic treatments—may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.
Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.
© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.